On 27 May 2024, IFPMA submitted a statement to the World Health Assembly on Provisional Agenda Item 17, WHO’s 14th General Programme of Work.

IFPMA welcomes the strategic focus of the 14th General Programme of Work (GPW14) and appreciates WHO’s efforts to consult with external stakeholders, including the private sector, throughout the drafting process. We reiterate our support for WHO’s overarching goal of “advancing health equity and health systems resilience” within an increasingly complex and changing world. There are “longer-term trends emergencies and crises” compared with the era of GPW13 that are significant, multi-faceted, and further complicate the ability of WHO to meet its strategic objectives. We remain fully committed to working constructively with WHO and, while we remain eager to continue our long-standing cooperation, we regret that WHO has not acknowledged the pharmaceutical industry as one of the “key health ‘contributing’ sectors” given our critical role in innovating for global health issues.

About IFPMA

IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.

To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.

ifpma.org

Media Contact

Elliot Dunster e.dunster@ifpma.org